Moreover, these ligands are predominantly expressed by tumor cells, tumor-infiltrating myeloid cells, and antigen-presenting cells (APCs), underlining TIGIT’s role in TME-specific T cell immunosuppression [121]. This evidence concerns the gene TIGIT and neoplasm.